Human Baculoviral IAP repeat-containing protein 7 (BIRC7) ELISA kit; KIAP; LIVIN; ML-IAP; MLIAP; RNF50; baculoviral IAP repeat-containing protein 7; kidney inhibitor of apoptosis protein; livin inhibitor of apoptosis; livin inhibitor-of-apoptosis; melanoma inhibitor of a; baculoviral IAP repeat-containing 7

For Research Use Only. Not for use in diagnostic procedures.

Store all reagents at 2-8 degree C

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of BIRC7 elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS9330268 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the baculoviral IAP repeat-containing 7 (BIRC7) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing BIRC7. The ELISA analytical biochemical technique of the MBS9330268 kit is based on BIRC7 antibody-BIRC7 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect BIRC7 antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, BIRC7. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

32,798 Da

baculoviral IAP repeat containing 7

baculoviral IAP repeat-containing protein 7; RING finger protein 50; livin inhibitor of apoptosis; kidney inhibitor of apoptosis protein; melanoma inhibitor of apoptosis protein

Baculoviral IAP repeat-containing protein 7

KIAP; LIVIN; MLIAP; RNF50; UNQ5800/PRO19607/PRO21344; KIAP; ML-IAP; Truncated livin; p30-Livin; tLivin??[Similar Products]

BIRC7_HUMAN

This gene encodes a member of the inhibitor of apoptosis protein (IAP) family, and contains a single copy of a baculovirus IAP repeat (BIR) as well as a RING-type zinc finger domain. The BIR domain is essential for inhibitory activity and interacts with caspases, while the RING finger domain sometimes enhances antiapoptotic activity but does not inhibit apoptosis alone. Elevated levels of the encoded protein may be associated with cancer progression and play a role in chemotherapy sensitivity. Alternative splicing results in multiple transcript variants [provided by RefSeq, Jul 2013]

BIRC7: Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing. Binds to CASP9. Interaction with DIABLO/SMAC via the BIR domain disrupts binding to CASP9 and apoptotic suppressor activity. Interacts with TAB1. In vitro, interacts with CASP3 and CASP7 via its BIR domain. Isoform 1 and isoform 2 are expressed at very low levels or not detectable in most ***** tissues. Detected in ***** heart, placenta, lung, lymph node, spleen and ovary, and in several carcinoma cell lines. Isoform 2 is detected in fetal kidney, heart and spleen, and at lower levels in ***** brain, skeletal muscle and peripheral blood leukocytes. Belongs to the IAP family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Ligase; Ubiquitin ligase; EC 6.3.2.-; Ubiquitin conjugating system; Apoptosis

Chromosomal Location of Human Ortholog: 20q13.3

Cellular Component: Golgi apparatus; spindle microtubule; cytoplasm; nucleus

Molecular Function: protein binding; enzyme binding; zinc ion binding; caspase inhibitor activity; ubiquitin-protein ligase activity; cysteine protease inhibitor activity; ligase activity

Biological Process: regulation of signal transduction; protein ubiquitination; activation of JNK activity; negative regulation of apoptosis; regulation of cell proliferation

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.